NuCana plc Short Interest Down 29.9 percent in February
NCNA Stock | USD 1.27 0.02 1.60% |
About 63% of NuCana PLC's investor base is looking to short. The analysis of the overall investor sentiment regarding NuCana PLC suggests that many traders are alarmed. The current market sentiment, together with NuCana PLC's historical and current headlines, can help investors time the market. In addition, many technical investors use NuCana PLC stock news signals to limit their universe of possible portfolio assets.
NuCana |
NuCana plc was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 23,200 shares, a drop of 29.9 percent from the January 31st total of 33,100 shares. Currently, 0.1 percent of the companys shares are sold short. Based
Read at thelincolnianonline.com
NuCana PLC Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards NuCana PLC can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NuCana PLC Fundamental Analysis
We analyze NuCana PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NuCana PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NuCana PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
NuCana PLC is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
NuCana PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NuCana PLC stock to make a market-neutral strategy. Peer analysis of NuCana PLC could also be used in its relative valuation, which is a method of valuing NuCana PLC by comparing valuation metrics with similar companies.
Peers
NuCana PLC Related Equities
CDTX | Cidara Therapeutics | 5.73 | ||||
ZURA | Zura Bio | 3.64 | ||||
ALXO | Alx Oncology | 2.82 | ||||
INZY | Inozyme Pharma | 1.68 | ||||
APLT | Applied Therapeutics | 0.88 | ||||
ZVSA | ZyVersa Therapeutics | 0.00 | ||||
DAWN | Day One | 0.47 | ||||
CTMX | CytomX Therapeutics | 1.79 | ||||
SLN | Silence Therapeutics | 2.27 | ||||
MREO | Mereo BioPharma | 3.12 | ||||
VINC | Vincerx Pharma | 5.00 | ||||
ABOS | Acumen Pharmaceuticals | 6.88 | ||||
CRVS | Corvus Pharmaceuticals | 8.66 | ||||
RANI | Rani Therapeutics | 10.75 | ||||
TNYA | Tenaya Therapeutics | 24.86 |
Complementary Tools for NuCana Stock analysis
When running NuCana PLC's price analysis, check to measure NuCana PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NuCana PLC is operating at the current time. Most of NuCana PLC's value examination focuses on studying past and present price action to predict the probability of NuCana PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NuCana PLC's price. Additionally, you may evaluate how the addition of NuCana PLC to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |